Novolog (Pharm-Up 1966) Ltd
TASE:NVLG Stock Report
Novolog (Pharm-Up 1966) Past Earnings Performance Novolog (Pharm-Up 1966)'s earnings have been declining at an average annual rate of -18.3%, while the Healthcare industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 12.2% per year.
Key information
-18.3%
Earnings growth rate
Healthcare Industry Growth 14.9% Revenue growth rate 12.2% Return on equity -3.9% Net Margin -1.0% Next Earnings Update 20 Nov 2024
Recent past performance updates
Novolog (Pharm-Up 1966) Ltd to Report Q3, 2024 Results on Nov 20, 2024 Nov 04
Second quarter 2024 earnings released: EPS: ₪0.026 (vs ₪0.023 in 2Q 2023) Aug 22
Novolog (Pharm-Up 1966) Ltd to Report Q2, 2024 Results on Sep 04, 2024 Aug 20
First quarter 2024 earnings released: EPS: ₪0.024 (vs ₪0.02 loss in 1Q 2023) May 21
Novolog (Pharm-Up 1966) Ltd to Report Q1, 2024 Results on May 21, 2024 May 14
Full year 2023 earnings released: ₪0.082 loss per share (vs ₪0.094 profit in FY 2022) Mar 27
Show all updates
Novolog (Pharm-Up 1966) Ltd to Report Q3, 2024 Results on Nov 20, 2024 Nov 04
Upcoming dividend of ₪0.029 per share Aug 27
Second quarter 2024 earnings released: EPS: ₪0.026 (vs ₪0.023 in 2Q 2023) Aug 22
Novolog (Pharm-Up 1966) Ltd to Report Q2, 2024 Results on Sep 04, 2024 Aug 20 Novolog (Pharm-Up 1966) Ltd, Annual General Meeting, Aug 05, 2024 Jul 02
First quarter 2024 earnings released: EPS: ₪0.024 (vs ₪0.02 loss in 1Q 2023) May 21
Novolog (Pharm-Up 1966) Ltd to Report Q1, 2024 Results on May 21, 2024 May 14
Full year 2023 earnings released: ₪0.082 loss per share (vs ₪0.094 profit in FY 2022) Mar 27
Novolog (Pharm-Up 1966) Ltd to Report Q4, 2023 Results on Mar 26, 2024 Mar 06
New minor risk - Share price stability Feb 10
Third quarter 2023 earnings released: EPS: ₪0.001 (vs ₪0.02 in 3Q 2022) Nov 22
Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Nov 05
Investor sentiment improves as stock rises 17% Nov 05
Second quarter 2023 earnings released: EPS: ₪0.023 (vs ₪0.024 in 2Q 2022) Aug 23
Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital Jul 25
First quarter 2023 earnings released: ₪0.02 loss per share (vs ₪0.024 profit in 1Q 2022) Jun 01
Investor sentiment deteriorates as stock falls 15% Mar 30
Full year 2022 earnings released: EPS: ₪0.094 (vs ₪0.084 in FY 2021) Mar 21
Investor sentiment deteriorates as stock falls 17% Feb 26
Novolog (Pharm-Up 1966) Ltd to Report Q4, 2022 Results on Mar 20, 2023 Feb 07
Investor sentiment deteriorates as stock falls 15% Jan 30
Novolog (Pharm-Up 1966) Ltd Appoints Tami Gottlieb as an Independent Non-Executive Director Jan 17
Third quarter 2022 earnings released: EPS: ₪0.02 (vs ₪0.02 in 3Q 2021) Nov 18
Insufficient new directors Nov 16
Novolog (Pharm-Up 1966) Ltd to Report Q3, 2022 Results on Nov 16, 2022 Nov 02
Second quarter 2022 earnings released: EPS: ₪0.024 (vs ₪0.02 in 2Q 2021) Aug 14
Insufficient new directors Aug 01
Novolog (Pharm-Up 1966) Ltd to Report Q2, 2022 Results on Aug 10, 2022 Jul 28
Insufficient new directors Jul 02
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 22
Novolog (Pharm-Up 1966) Ltd to Report Q1, 2022 Results on May 18, 2022 May 19
Investor sentiment improved over the past week Apr 03
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 17
Novolog (Pharm-Up 1966) Ltd to Report Q4, 2021 Results on Mar 14, 2022 Feb 25
Third quarter 2021 earnings released: EPS ₪0.022 (vs ₪0.021 in 3Q 2020) Nov 21
I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease May 07
Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend Apr 14
Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality Mar 24
Upcoming dividend of ₪0.032 per share Mar 23
Full year 2020 earnings released: EPS ₪0.086 (vs ₪0.026 in FY 2019) Mar 23
Novolog (Pharm-Up 1966) Ltd to Report Fiscal Year 2020 Results on Mar 17, 2021 Mar 17
Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? Mar 09
How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own? Feb 15
New 90-day low: ₪2.76 Feb 01
Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years Jan 25
Novolog (Pharm-Up 1966) Ltd announced that it has received ILS 119.999999 million in funding Dec 31
How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid? Dec 29
With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting Dec 08
Third quarter 2020 earnings released: EPS ₪0.021 Nov 28
Market bids up stock over the past week Nov 18
New 90-day high: ₪3.20 Nov 17
New 90-day high - ₪3.09 Jul 20
Revenue & Expenses Breakdown
How Novolog (Pharm-Up 1966) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History TASE:NVLG Revenue, expenses and earnings (ILS Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Jun 24 1,683 -18 122 0 31 Mar 24 1,668 -20 124 0 31 Dec 23 1,643 -42 123 0 30 Sep 23 1,630 15 117 0 30 Jun 23 1,597 24 110 0 31 Mar 23 1,546 25 105 0 31 Dec 22 1,508 48 102 0 30 Sep 22 1,424 43 86 0 30 Jun 22 1,366 43 80 0 31 Mar 22 1,315 41 76 0 31 Dec 21 1,255 42 84 0 30 Sep 21 1,229 41 82 0 30 Jun 21 1,190 40 81 0 31 Mar 21 1,148 40 79 0 31 Dec 20 1,134 40 64 0 30 Sep 20 1,085 38 62 0 30 Jun 20 1,061 24 59 0 31 Mar 20 1,042 18 57 0 31 Dec 19 1,004 10 64 0 30 Sep 19 1,000 9 61 0 30 Jun 19 963 18 59 0 31 Mar 19 943 22 56 0 31 Dec 18 910 23 49 0 30 Sep 18 912 22 49 0 30 Jun 18 891 23 46 0 31 Mar 18 862 22 43 0 31 Dec 17 839 23 44 0 30 Sep 17 797 23 37 0 30 Jun 17 780 24 35 0 31 Mar 17 770 27 34 0 31 Dec 16 739 29 32 0 30 Sep 16 730 28 32 0 31 Dec 15 683 25 30 0 31 Dec 14 629 24 29 0 31 Dec 13 543 15 27 0
Quality Earnings: NVLG is currently unprofitable.
Growing Profit Margin: NVLG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NVLG is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.
Accelerating Growth: Unable to compare NVLG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVLG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.4%).
Return on Equity
High ROE: NVLG has a negative Return on Equity (-3.9%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
